drugset / Trial / NCT00420004

A Study for Participants With Major Depression

NCT00420004

Phase 2 Completed 469 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.

Timeline

Start
2006-12
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Escitalopram Small molecule 10 mg Oral
Comparator Escitalopram Small molecule 20 mg Oral
Subject edivoxetine Small molecule 3 mg Oral
Subject edivoxetine Small molecule 6 mg Oral
Subject edivoxetine Small molecule 9 mg Oral
Subject edivoxetine Small molecule 12 mg Oral